Defactinib has recently been granted breakthrough therapy designation by the FDA for the treatment of ovarian cancer, which thus could facilitate a timely investigation of the benefits of PTK2B/FAK inhibition also in FLT3-ITD mutated AML patients, based on the results of this study. This evidence concerns the gene PTK2B and acute myeloid leukemia.